These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31479946)

  • 1. Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapies.
    Corbaux P; El-Madani M; Tod M; Péron J; Maillet D; Lopez J; Freyer G; You B
    Eur J Cancer; 2019 Oct; 120():40-46. PubMed ID: 31479946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of the recommended phase 2 dose of molecular targeted agents.
    Hansen AR; Cook N; Amir E; Siu LL; Abdul Razak AR
    Cancer; 2017 Apr; 123(8):1409-1415. PubMed ID: 28182250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal biological dose: a systematic review in cancer phase I clinical trials.
    Fraisse J; Dinart D; Tosi D; Bellera C; Mollevi C
    BMC Cancer; 2021 Jan; 21(1):60. PubMed ID: 33441097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example.
    Sachs JR; Mayawala K; Gadamsetty S; Kang SP; de Alwis DP
    Clin Cancer Res; 2016 Mar; 22(6):1318-24. PubMed ID: 26597302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.
    Postel-Vinay S; Aspeslagh S; Lanoy E; Robert C; Soria JC; Marabelle A
    Ann Oncol; 2016 Feb; 27(2):214-24. PubMed ID: 26578728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013.
    Nikanjam M; Liu S; Kurzrock R
    Int J Cancer; 2016 Nov; 139(9):2135-41. PubMed ID: 27389805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs.
    Bullock JM; Rahman A; Liu Q
    Clin Cancer Res; 2016 Jun; 22(11):2630-8. PubMed ID: 27250934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring Ethnic Differences in Toxicity in Early-Phase Clinical Trials for Oncology Drugs.
    Ogura T; Morita S; Yonemori K; Nonaka T; Urano T
    Ther Innov Regul Sci; 2014 Sep; 48(5):644-650. PubMed ID: 30231453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials.
    Hazim A; Mills G; Prasad V; Haslam A; Chen EY
    J Natl Compr Canc Netw; 2020 Apr; 18(4):428-433. PubMed ID: 32259790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients.
    Nikanjam M; Liu S; Yang J; Kurzrock R
    Oncologist; 2017 May; 22(5):576-584. PubMed ID: 28424323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.
    Lu D; Lu T; Stroh M; Graham RA; Agarwal P; Musib L; Li CC; Lum BL; Joshi A
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):459-76. PubMed ID: 26811176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
    Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
    Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs.
    Jardim DL; Hess KR; Lorusso P; Kurzrock R; Hong DS
    Clin Cancer Res; 2014 Jan; 20(2):281-8. PubMed ID: 24190980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
    Drilon A; Eaton AA; Schindler K; Gounder MM; Spriggs DR; Harris P; Ivy SP; Iasonos A; Lacouture ME; Hyman DM
    Cancer; 2016 Apr; 122(8):1228-37. PubMed ID: 26916138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dose finding methods for targeted agents: new perspectives].
    Paoletti X; Postel-Vinay S; Servois V; Doussau A; Ollivier L; Le Tourneau C
    Bull Cancer; 2010 Dec; 97(12):1485-95. PubMed ID: 21220226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.